Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease

Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study

Allysta Pharmaceuticals, Inc. Raises $15 Million in Series A Financing to Advance Novel Therapeutic for Dry Eye Disease

Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma

Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at 2017 Annual Meeting of ARVO

Allysta Pharmaceuticals to present at QB3 – 2017 Life Science Pitch Summit in San Francisco

Allysta Pharmaceuticals to present at National Investment Banking Association in NYC

Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Franciso

Copy Of -Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease

Copy Of -Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study

Copy Of -Allysta Pharmaceuticals, Inc. Raises $15 Million in Series A Financing to Advance Novel Therapeutic for Dry Eye Disease

Copy Of -Allysta Pharmaceuticals Doses First Patient in Phase 2A Study in Glaucoma

Copy Of -Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at 2017 Annual Meeting of ARVO

Copy Of -Allysta Pharmaceuticals to present at QB3 – 2017 Life Science Pitch Summit in San Francisco

Copy Of -Allysta Pharmaceuticals to present at National Investment Banking Association in NYC

Copy Of -Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Franciso